Working on a project that could help expand MMV’s drug discovery pipeline and the global antimalarial toolbox? Our 23rd call for proposals is now open for compounds addressing key #malaria prevention, treatment and elimination needs. Deadline: 27 Feb. 👉 bit.ly/3XFUG8n

Can we afford #malaria eradication? Put benefits above costs & the answer is yes. Eradication will save lives and deliver major social & #economic returns. At #ASTMH25, Prof. Nonvignon underscored why we cannot afford not to pursue a malaria-free future 👉 bit.ly/4pzptQg

What can endemic countries learn from Zambia’s progress towards #malaria elimination? At #ASTMH25, Dr Busiku Hamainza shared how strong leadership, scaled interventions, real-time data and partner support are driving progress. 🎥 bit.ly/4rQ4bzJ

How can we eliminate the #malaria parasite with existing & new tools? Modelling helps assess strategies for developing and deploying interventions and guides R&D and access decisions. At #ASTMH25, Prof. Melissa Penny showed how it can accelerate progress 👉🎥 bit.ly/4rJzKea

Current #malaria prevention tools offer considerable protection, but new options are needed to simplify delivery and extend protection further. At #ASTMH25, Prof. Amewu highlighted the big bets driving next-gen prevention tools 🎥 bit.ly/3XHQswZ

Alan Magill believed that a business-as-usual approach to #malaria elimination is not enough. At #ASTMH25, MMV and @gatesfoundation.bsky.social put his vision into a contemporary context, reinforcing our shared belief that eradication is possible in our lifetime. 🎥👉 bit.ly/4oFwlus

Despite setbacks & emerging threats, progress against #malaria continues. Since 2000, billions of cases & millions of deaths have been averted & more countries are now malaria-free. Cabo Verde, Egypt, Georgia, Suriname & Timor-Leste show that zero malaria is possible.

#Malaria is often seen as inevitable, but it doesn’t have to be. Phase 3 results for GanLum, developed by Novartis & MMV, could further expand the antimalarial toolbox. But funding & political will remain the biggest barriers to access and #innovation 👉 bit.ly/3MIZabP

Scenes from last week’s co-creation workshop in Accra, where MMV & @deepmirror.bsky.social convened a group of Africa-based researchers convened to learn about & shape the continued development of the AI-powered Drug Discovery for Global Health platform. More 👉 bit.ly/4qeyz55

Children’s medicines lag nearly a decade behind adult treatments. @who.int’s GAP-f network is working to close this gap. Its recent #malaria PADO exercise – supported by MMV – set a research agenda to better address children’s needs. Report 👉 bit.ly/4pyfMBN

This year proved we can regain momentum against #malaria. To defeat it, we need broader access and new #innovations. MMV's CEO Martin Fitchet shares what’s needed in 2026 to accelerate progress through innovation & partnership.

The @gatesfoundation.bsky.social Goalkeepers Report warns child deaths are rising for the first time this century. Shrinking global health funding puts millions more at risk. For #malaria, the message is urgent: strengthen prevention, treatment & equitable access 👉 bit.ly/48rzNEc

A powerful trio of #malaria prevention tools – vector control, chemoprevention & vaccines – helped protect millions last year. MMV works with national malaria control programmes & African manufacturers to continue expanding access to SMC for children and pregnant women.

The #WorldMalariaReport is clear: drug resistance is advancing. Our response must be just as clear: new meds with new mechanisms of action. Collaboration, commitment & funding can keep us ahead of resistance & help deliver next-gen meds to ensure #malaria is no longer a threat.

On 18 January, graduate researcher Camille Gourjault is taking the fight against #malaria from the lab to the streets, running the Hong Kong Marathon in support of MMV’s mission to develop and deliver the next generation of antimalarials. Learn more 👉 bit.ly/3KMhT5K

Antimalarial drug resistance won’t wait, and neither should we. At the #WorldMalariaReport launch in the UK Parliament, MMV’s Cristina Donini highlighted our efforts to stay one step ahead of resistance and the role UK science & innovation play in the fight against #malaria.

Can AI advance #malaria elimination & support an inclusive global health system? In @devex.com, MMV experts highlight 3 opportunities: • Faster next-gen drug discovery • Co-creating innovation with endemic-country researchers • Turning complex data into actionable insights More 👉 bit.ly/3Mxkilk

Quality-assured antimalarials made locally are vital to reducing the #malaria burden in Africa. With MMV support, Swipha Nigeria’s SP has achieved @who.int prequalification, and the US Gov has procured 5M doses, protecting +1.6M pregnant women in Nigeria. More 👉 bit.ly/3MhXUfT

Cabo Verde went from #malaria once being the leading cause of death to earning @who.int certification as malaria-free in 2024. A new @gatesfoundation.bsky.social article highlights key lessons: political will, collaboration, smart investment & strong health systems 👉 bit.ly/4pI2tOV

The @who.int 2025 World malaria report brings a clear message: drug resistance threatens to undo hard-won gains against #malaria. With progress stalling, we must double down on innovation, surveillance and long-term commitment to stay ahead of resistance 👉 bit.ly/48JynVs

On International Day of Persons with Disabilities. MMV is proud to be part of the @who.int Disability Health Equity Network. The relationships built through the network will help us define what disability inclusion means for MMV. #IDPD #DisabilityDay #Malaria #GlobalHealth

#ClimateChange is expanding #malaria-risk zones across Africa, a new Global Change Biology study warns, potentially putting millions more at risk. We need innovative, accessible tools to stay ahead 👉 bit.ly/4iyhTTu

Can AI help democratize the global fight against #malaria? In @healthpolicywatch.bsky.social, MMV’s Jeremy Burrows explains how AI could speed up drug discovery and how a new platform with @deepmirror.bsky.social aims to make these tools more accessible worldwide. Read: bit.ly/4aj84GU

How do #malaria parasites survive in the mosquito gut? Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools. Read more in @nature.com: bit.ly/3XeaP4B

Press release 📢 Announcing MMV's new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for #malaria prevention. 🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.

Vivax #malaria relapses keep patients trapped in a cycle. The Partnership for Vivax Elimination (PAVE) has been generating evidence from across endemic countries to support country elimination goals.

Is #malaria eradication still within reach? Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment. 🎥 Watch it here: bit.ly/4inePJY

@globalhealthedctp3.bsky.social builds and fosters Africa–Europe research partnerships transforming innovative science into global health impact, including the consortium behind Coartem Baby, the first #malaria treatment for infants 2 to <5 kg. Read more: bit.ly/4ii8b7w

Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25

At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance. MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials. #WAAW25

How can collaboration, bold science & sustained funding help tackle antimalarial drug resistance? MMV's Cristina Donini shares how resistance threatens the #malaria agenda & discusses our strategy to stay ahead of it. Read more via Mediaplanet: bit.ly/4p9F9Jw #WAAW25

Drug resistance threatens #malaria elimination and global health security. Researchers across endemic countries, Japan and Europe are working together to develop new innovations and ensure communities can access effective, affordable tools. More here: bit.ly/3X67ogi

In case you missed it: last week, @novartis.bsky.social & MMV announced positive Phase 3 results for GanLum, a novel, non-artemisinin antimalarial. This milestone comes amid urgent calls to tackle emerging drug resistance. Read more in @npr.org: bit.ly/4oTKuVx

What if drug resistance caused the #malaria medicines millions rely on to stop working? With signs of partial resistance emerging again, we must act now to protect the efficacy of existing tools and develop new interventions with stronger barriers to resistance. #WAAW25

Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future. MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x #WAAW25

Press release: @who.int has prequalified the first-ever paediatric formulations of primaquine, paving the way for improved access to critical treatment for children in malaria-endemic regions 👉 bit.ly/43DdY1r

As #COP30 begins, the link between #climatechange & health is more urgent than ever & a major leadership opportunity. Read an op-ed published in @Devex on long-lasting, single-dose tools that could transform #malaria protection in unpredictable climate: bit.ly/4i6vhhe

For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P

This week at #ASTMH25, the Partnership for Vivax Elimination (PAVE) network came together to show what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.

We are the impatient optimists who believe in #malaria eradication in our lifetime. Today at #ASTMH25, MMV & @gatesfoundation.bsky.social convened leading global health experts for a special symposium to reaffirm their shared belief in a malaria-free future. Stay tuned for the video.

MMV is at #ASTMH25! Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda. See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC

Heading to #ASTMH2025 in Toronto? 🇨🇦 MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC

MMV staff are celebrating #MalariaDayInTheAmericas by joining the Brazilian #MedTrop25 Conference in Belém this week!

Symposium: MMV & partners at #ASTMH2025 📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention Speakers & topics 👉 bit.ly/3KVqVx7

📣 Applications are open! The SAHRI Fellowship (2026–2029), funded by @globalhealthedctp3.bsky.social, supports mid-career scientists in sub-Saharan Africa advancing health research & innovation in infectious diseases. Apply now 👉 bit.ly/4qfTdT6

MMV & Chiang Mai University have launched a qualitative study in Thailand on paediatric formulations of primaquine and tafenoquine for P. vivax #malaria relapse prevention, exploring perceptions around their use with G6PD testing.

Malaria can become deadly within hours. Through SEMA ReACT, MMV & partners are studying rectal artesunate use in remote Zambia & DRC to improve severe #malaria care. Join us at #ASTMH2025 (11 Nov) for a symposium sharing interim results & insights 👉 bit.ly/46Z7ADQ

Diversifying the use of #malaria meds through the deployment of MFT can keep us one step ahead of resistance. MMV & partners recently conducted a feasibility study in Kenya demonstrating that an MFT approach is feasible, with adequate resources 👉 bit.ly/3IVeQYh

Are you subscribed to MMV’s monthly newsletter? Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV 👉 bit.ly/MMVnewsletter

MMV joins the global health community in mourning the passing of our friend & colleague, Prof. Jean Louis Abdourahim Ndiaye. As we honour Prof. Ndiaye’s memory, we extend our deepest condolences to his family, close friends & colleagues around the world: shorturl.at/VSzLG